AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.80

22 Sep
2023

0.000

OPEN

$0.80

0.000

HIGH

$0.81

93,876

LOW

$0.80

TARGET
$1.475 84.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 0.5 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 2019202020212022
EPS Basic xxxxxxxxx-2.3
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx37.4 M
Book Value Per Share xxxxxxxxx27.2
Net Operating Cash Flow xxxxxxxxx-10.9 M
Net Profit Margin xxxxxxxxx-21.13 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2019202020212022
Return on Capital Employed xxxxxxxxx-10.77 %
Return on Invested Capital xxxxxxxxx-10.07 %
Return on Assets xxxxxxxxx-8.90 %
Return on Equity xxxxxxxxx-10.77 %
Return on Total Capital xxxxxxxxx-9.82 %
Free Cash Flow ex dividends xxxxxxxxx-15.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2019202020212022
Short-Term Debt xxxxxxxxx1 M
Long Term Debt xxxxxxxxx5 M
Total Debt xxxxxxxxx5 M
Goodwill - Gross xxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxx53 M
Price To Book Value xxxxxxxxx2.85

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2019202020212022
Capex xxxxxxxxx4.6 M
Capex % of Sales xxxxxxxxx12.28 %
Cost of Goods Sold xxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxx37 M
Research & Development xxxxxxxxx8 M
Investments - Total xxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

02/06/2023

1

Buy

$1.45

81.25%

FY23 earnings (EBITDA) for Aroa Biosurgery beat Bell Potter's forecast, while the net loss after tax was in line. The combination of an increased sales force (40 from 33) and growth in active Myriad accounts largely propelled the 23% increase in revenue.

For FY24, management guided to product revenue of between NZ$72-75m and earnings in the range of NZ$1-2m, with the gross margin improving to 85%.

The broker highlights upcoming growth drivers which includes the product launches of Myriad Morcells (fine) and Symphony during FY24. 

The Buy rating and $1.45 target are unchanged.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.74 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.84 cents.
Access Stockbroker Research History >

ARX STOCK CHART

FNArena News on ARX

1
Rudi’s Views: August 2023 – Winners & Losers

Sep 13 2023 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 03, 2023

Aug 03 2023 - Daily Market Reports
3
Rudi’s View: Low Expectations Not Low Enough?

Jul 19 2023 - Rudi's View
4
In Brief: Retail, Radiology & Wilsons’ Best Ideas

Jun 09 2023 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Jun 06, 2023

Jun 06 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
2
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
3
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
4
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
5
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
6
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
7
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
8
Dr Boreham’s Crucible: PolyNovo

Jul 06 2023 - Small Caps
9
CSL Disappoints But Brokers Retain The Faith

Jun 15 2023 - Australia
10
Dr Boreham’s Crucible: Dimerix

Jun 07 2023 - Small Caps